Prosecution Insights
Last updated: April 19, 2026

Simcere Zaiming Pharmaceutical Co. Ltd.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
0
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18554426 UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR HABTE, KAHSAY 1624 Non-Final OA Oct 06, 2023
18266125 ANTI-EGFR NANOBODY AND USE THEREOF SHUPE, ELIZABETH A 1643 Non-Final OA Jun 08, 2023
18265150 ANTI-CD22 NANO ANTIBODY AND USE THEREOF GAMETT, DANIEL C 1647 Non-Final OA Jun 02, 2023

Managing Simcere Zaiming Pharmaceutical Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month